SAN DIEGO — Sequenom, Inc. (NASDAQ: SQNM) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock, offered at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering are expected to be $53.95 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sequenom. Sequenom has granted the underwriters a 30-day option to purchase up to an aggregate of 1,950,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about January 25, 2012, subject to customary closing conditions. Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, capital expenditures, working capital and general administrative expenses.

Jefferies & Company, Inc. is acting as sole book-running manager for the offering, and Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. are acting as co-managers for the offering.

The securities described above are being offered by Sequenom pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”), which the SEC declared effective on December 21, 2011. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at [email protected].

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California.